$0.36
-0.06 (-13.51%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SKYE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 2 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd) · FINRA short interest 12.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090Percent change in body weight (main study)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Nimacimab injection, Nimacimab placebo injection, Nimacimab 300 mg injection · Combination product: semaglutide injection | Obesity | 136 | 2026-11-20 | in 93 d | 2026-01-14 |
| Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressureNCT06144918results2026-01-14Change From Baseline in Ocular Hypertension as Measured by Intraocular Pressure (IOP)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: Original, version 1.0 ↗ · Statistical Analysis Plan: Version 2.0 ↗ · Informed Consent Form ↗ | Phase 2 | Completed | Drug: SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%, SBI-100 Ophthalmic Emulsion, Placebo | Primary Open Angle Glaucoma, Ocular Hypertension | 56 | 2024-02-22actual | — | 2026-01-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19